Combined study on the single nucleotide polymorphisms in the follicle-stimulating hormone receptor (Ser680Asn) and anti-Müllerian hormone receptor type II (−482A>G) as genetic markers in assisted reproduction

Abstract Background Infertile women may have underlying genetic abnormalities. There is, at present, a significant number of studies on the relation between the follicle stimulating hormone receptor (FSHR) or anti-Müllerian hormone type II receptor (AMHRII) polymorphisms and response to in-vitro fertilisation (IVF) treatment. However, it is not yet clear which genotype or combination of genotypes is favourable towards a better ovarian stimulation and pregnancy outcome. Materials and methods In this study we assessed the distribution of the genotypes of FSHR Ser680Asn and of AMHRII −482A>G gene polymorphisms in a group of 126 infertile women and a control group of 100 fertile women by using real-time polymerase chain reaction (RT-PCR). Results Statistical analysis showed that the frequency of the genotypes is similar in both control and IVF/ intracytoplasmic sperm injection (ICSI) groups. Further investigation of the frequency of the nine possible combinations of these polymorphisms in the groups revealed no correlation between infertility and combination of the polymorphisms. Women with one polymorphism have on average 5.5 units higher levels of AMH compared to women carrying no polymorphism. In women with no polymorphisms, for each unit of FSH increase, the average concentration of blood AMH is expected to be 72% lower. Conclusion The distribution of the FSHR Ser680Asn and of the AMHRII −482A>G gene polymorphisms, in the Greek population is similar in fertile and infertile women. The study showed that FSH and AMH correlated levels in certain cases could be used to estimate a patient’s ovarian reserve.

[1]  V. Manolopoulos,et al.  Pharmacogenomics in IVF: A New Era in the Concept of Personalized Medicine , 2019, Reproductive Sciences.

[2]  S. Esteves,et al.  Clinical relevance of genetic variants of gonadotrophins and their receptors in controlled ovarian stimulation: a systematic review and meta-analysis , 2018, Human reproduction update.

[3]  D. Santi,et al.  Pharmacogenetics of G-protein-coupled receptors variants: FSH receptor and infertility treatment. , 2018, Best practice & research. Clinical endocrinology & metabolism.

[4]  S. Ku,et al.  FSH receptor gene p. Thr307Ala and p. Asn680Ser polymorphisms are associated with the risk of polycystic ovary syndrome , 2017, Journal of Assisted Reproduction and Genetics.

[5]  C. Peterson,et al.  Female infertility, infertility-associated diagnoses, and comorbidities: a review , 2017, Journal of Assisted Reproduction and Genetics.

[6]  H. Jarjanazi,et al.  Associations of Polymorphisms in Anti-Müllerian Hormone (AMH Ile49Ser) and its Type II Receptor (AMHRII -482 A>G) on Reproductive Outcomes and Polycystic Ovary Syndrome: a Systematic Review and Meta-Analysis , 2016, Cellular Physiology and Biochemistry.

[7]  Ioannis Georgiou,et al.  The ovarian response to standard gonadotropin stimulation is influenced by AMHRII genotypes , 2016, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[8]  J. Clements,et al.  Single nucleotide polymorphisms in clinics: Fantasy or reality for cancer?* , 2015, Critical reviews in clinical laboratory sciences.

[9]  T. Hamatani,et al.  Infertility etiologies are genetically and clinically linked with other diseases in single meta-diseases , 2015, Reproductive Biology and Endocrinology.

[10]  Qingyang Huang,et al.  Genetic study of complex diseases in the post-GWAS era. , 2015, Journal of genetics and genomics = Yi chuan xue bao.

[11]  P. Drakakis,et al.  Single nucleotide polymorphisms in the Anti-Müllerian hormone (AMH Ile49Ser) and Anti-Müllerian hormone type II receptor (AMHRII −482 A>G) as genetic markers in assisted reproduction technology , 2015, Journal of Assisted Reproduction and Genetics.

[12]  J. Llácer,et al.  Pharmacogenetics of ovarian response. , 2014, Pharmacogenomics.

[13]  S. Sørensen,et al.  Recent progress in the utility of anti-Müllerian hormone in female infertility , 2014, Current opinion in obstetrics & gynecology.

[14]  R. Fanchin,et al.  The physiology and clinical utility of anti-Mullerian hormone in women. , 2014, Human reproduction update.

[15]  D. Loutradis,et al.  Genetic profile of SNP(s) and ovulation induction. , 2012, Current pharmaceutical biotechnology.

[16]  D. Loutradis,et al.  ESR1, ESR2 and FSH receptor gene polymorphisms in combination: a useful genetic tool for the prediction of poor responders. , 2012, Current pharmaceutical biotechnology.

[17]  A. Stavreus-Evers,et al.  Genetic predictors of controlled ovarian hyperstimulation: where do we stand today? , 2011, Human reproduction update.

[18]  S. Kalantar,et al.  Investigating the association between polymorphism of follicle-stimulating hormone receptor gene and ovarian response in controlled ovarian hyperstimulation , 2011, Journal of human reproductive sciences.

[19]  P. Devroey,et al.  Approaches to improve the diagnosis and management of infertility , 2009, Human reproduction update.

[20]  P. Drakakis,et al.  Pharmacogenetics in Ovarian Stimulation—Current Concepts , 2008, Annals of the New York Academy of Sciences.

[21]  A. Uitterlinden,et al.  Anti-Müllerian hormone and anti-Müllerian hormone type II receptor polymorphisms are associated with follicular phase estradiol levels in normo-ovulatory women. , 2007, Human reproduction.

[22]  F. Morón,et al.  Human controlled ovarian hyperstimulation outcome is a polygenic trait. , 2004, Pharmacogenetics.

[23]  E. Nieschlag,et al.  Isoforms and single nucleotide polymorphisms of the FSH receptor gene: implications for human reproduction. , 2002, Human reproduction update.

[24]  A. Roses,et al.  The use of single nucleotide polymorphisms in the isolation of common disease genes. , 2000, Pharmacogenomics.

[25]  R. Scott,et al.  Prognostic assessment of ovarian reserve. , 1995, Fertility and sterility.

[26]  E. Wallach Pitfalls in evaluating ovarian reserve. , 1995, Fertility and sterility.